The New Way to protect. prevent.
We are working to change the world with the first universal influenza vaccine.
While competitors' emphasis on sequence conservation makes sense, it is doubtful that sequence conservation (existence of mutations) and invariance (tolerance for mutations) are equivalent. More importantly, InvVax experimental data does not support this equivalence.
We have developed a method to directly determine the level of invariance at each unit of every flu protein. We have systematically assigned a "variance quotient" to every flu protein unit, allowing us to identify those stretches that are truly invariant. Based on this systematic analysis of 13,000 mutations, we have compiled a comprehensive list of the most invariant stretches, which include the optimal vaccine targets.
Technology Platform For HIV, Hepatitis
Using the same patented methodology that helped us identify ideal influenza vaccine targets, we can also map and identify invariant regions on other high-value viruses, such as HIV, Hepatitis B and Hepatitis C.
As for HIV, research is still in pre-development phase: a different methodology (from that of flu) has been conceived to determine the variance quotient at each unit of its proteins.